Dianthus Therapeutics, Inc. /DE/ Other Comprehensive Income (Loss), Net of Tax
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Other Comprehensive Income (Loss), Net of Tax of $718.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2024-11-07
- Dianthus Therapeutics, Inc. /DE/ other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was $718.00K, a 4686.67% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was -$10.00K, a 126.32% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was -$74.00K, a 171.15% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $15.00K.
- Dianthus Therapeutics, Inc. /DE/ other comprehensive income (loss), net of tax for fiscal 2023 was $208.00K.
- Dianthus Therapeutics, Inc. /DE/ other comprehensive income (loss), net of tax for fiscal 2022 was -$161.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | $718.00K 10-Q · filed 2024-11-07 | $708.00K derived: sum of 2 quarters · filed 2024-11-07 | $634.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2024-06-30 | -$10.00K 10-Q · filed 2024-11-07 | -$84.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2024-03-31 | -$74.00K 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $208.00K 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $15.00K 10-Q · filed 2024-11-07 | $53.00K derived: sum of 2 quarters · filed 2024-11-07 | $157.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $38.00K 10-Q · filed 2024-11-07 | $142.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $104.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | -$161.00K 10-K · filed 2024-03-21 | |||
| 2022-09-30 | -$150.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |